<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prafa Alif Rahmawan</style></author><author><style face="normal" font="default" size="100%">Yetti Hernaningsih</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Natural Compounds in Clot Waveform Analysis and D-Dimer Modulation: Implications for COVID-19 Diagnosis and Prognosis</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Activated partial thromboplastin time</style></keyword><keyword><style  face="normal" font="default" size="100%">Clot waveform analysis</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">D-dimer</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2024</style></year><pub-dates><date><style  face="normal" font="default" size="100%">December 2024</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">16</style></volume><pages><style face="normal" font="default" size="100%">1373-1378</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Objectives:&lt;/strong&gt; Patients diagnosed with coronavirus disease (COVID-19) may develop hypercoagulopathy. A thromboelastogram can detect hypercoagulopathy, but it is not commonly available in all healthcare facilities. Understanding the clot waveform analysis (CWA) parameters of the CS-2500 coagulation analyzer in patients diagnosed with COVID-19 may help determine whether it can serve as an alternative. &lt;strong&gt;Methods:&lt;/strong&gt; This study measured the amounts of activated partial thromboplastin time (aPTT)-based CWA, aPTT, plasma prothrombin time (PPT), and D-dimer using the CS-2500 autoanalyzer in 177 patients confirmed with COVID-19 and 110 patients without COVID-19. Retrospective data collection was conducted using electronic medical records. COVID-19 and non-COVID-19 were distinguished by the SARS-COV-2 PCR results.&lt;strong&gt; Results: &lt;/strong&gt;Substantial differences were observed in the aPTT-based CWA parameters, including maximum coagulation velocity (Vmax), maximum coagulation acceleration (Amax), and maximum coagulation deceleration (Dmax) (p = 0.03, p = 0.03, and p = 0.02), between the COVID-19 and non-COVID-19 groups but not between survivors and non-survivors. Additionally, a substantial difference was identified in the D-dimer between the two groups (p = 0.002 and p &amp;lt; 0.001). The difference in D-dimer between both groups could be explained by the fact that non-survivors have a more prominent hypercoagulable state. &lt;strong&gt;Conclusions: &lt;/strong&gt;While the D-dimer may be a better indicator of mortality in COVID-19 patients, the aPTT-based CWA characteristics may be more helpful in differentiating between COVID-19 and non-COVID-19 patients. Further investigations on treatment interference and the specificity of this method to predict hypercoagulable states are warranted.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1373</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Prafa Alif Rahmawan&lt;sup&gt;1&lt;/sup&gt;, Yetti Hernaningsih&lt;sup&gt;2,3*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Student of Specialist, Clinical Pathology Study Program, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Clinical Pathology, Dr. Soetomo General Academic Hospital, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>